6010-3724505 admin@juzlab.net
0 Items
GOLDMAN SACHS: These 8 underappreciated biotech stocks are cheap and poised to explode higher

GOLDMAN SACHS: These 8 underappreciated biotech stocks are cheap and poised to explode higher

source
Shutterstock/18percentgrey

It’s been a big year for biotech companies.

A big number of biotech IPOs debuted on the stock market this year. Yet biotech stocks have declined this year as investors soured on the sector and amid concerns about rising interest rates, according to a Goldman Sachs report released Wednesday. With so many companies to choose from, here are the ones Goldman recommends owning.


Bluebird Bio (BLUE)

caption
In this 2011 image, tiny beads (yellow) are used to force T-cells to divide before they are given to leukemia patients.
source
University of Pennsylvania via Microbe World / Flickr

Cambridge-based company Bluebird Bio is a clinical stage company that develops gene therapies for genetic diseases and T cell-based immunotherapies.

Goldman is expecting a first look at early-stage data for Bluebird’s bb21217 treatment for multiple myeloma, a form of blood cancer, in December.

Get the latest BLUE stock quote here.


BioMarin Pharmaceutical (BMRN)

source
Markets Insider

BioMarin focuses on developing treatments for rare diseases. It’s expected to report third quarter results this week.

Goldman says that the company has room for growth with its recently launched Palynziq, which treats adult phenylketonuria, a rare inherited disorder in which the body can’t process an amino acid called phenylalanine

Goldman also said treatments with potential include vosoritide (treats achondroplasia, a type of short-limbed dwarfism), val-rox (hemophilia A gene therapy), and BMN250 (treats Sanfilippo Syndrome B).

Get the latest BMRN stock here.


CRISPR Therapeutics (CRSP)

source
Markets Insider

CRISPR Therapeutics is using the CRISPR/Cas9 complex to edit genes and has programs in sickle cell disease, immuno-oncology, and regenerative medicines.

Get the latest CRSP stock here.


GW Pharmaceuticals (GWPH)

source
Markets Insider

GW Pharmaceuticals is known for using a marijuana-based drug to help treat multiple sclerosis.

Goldman is positive about the company’s fall launch of Epidiolex, which is a marijuana-based product for certain types of epilepsy.

Get the latest GWPH stock here.


Intercept Pharmaceuticals (ICPT)

source
Markets Insider

Intercept Pharmaceuticals develops treatments for patients with liver diseases.

The company’s drug Ocaliva remains the key driver of growth. Further, Goldman expects positive phase 3 results from a trial of the drug in patients with cirrhosis who aren’t showing symptoms of the liver disease yet.

Get the latest ICPT stock here.


Incyte Corporation (INCY)

source
Markets Insider

Incyte offers the drug Jakafi in the US to treats a bone marrow disorder called myelofibrosis and a type of blood cancer.

Goldman has faith in INCY’s diverse clinical portfolio and three New Drug Applications expected in the next 12-18 months.

Get the latest INCY stock here.


Sarepta Therapeutics (SRPT)

source
Markets Insider

Sarepta Therapeutics focuses on developing treatments for rare neuromuscular diseases.

Goldman predicts sales will continue to remain high for Exondys, the company’s treatment for Duchenne muscular dystrophy, and it will continue advancing its pipeline for treatments of rare disease.

Get the latest SRPT stock here.


SAGE Therapeutics (SAGE)

source
Markets Insider

SAGE Therapeutics focuses on developing treatments for central nervous system disorders.

Goldman expects a positive FDA advisory committee outcome in November for brexanolone, which treats postpartum depression. It also expects positive phase 3 results for a different treatment for the condition before the end of the year.

Get the latest SAGE stock here.

A blockbuster gene-editing tool has been linked to cancer — here’s how worried you should be

A blockbuster gene-editing tool has been linked to cancer — here’s how worried you should be

source
American Cancer Society/Getty Images
  • Bold headlines linking blockbuster gene-editing tool CRISPR to cancer sent stocks in companies trying to bring the technology to medicine tumbling.
  • But scientists who study the technique say the concerns are overblown at best and an incorrect interpretation of the science at worst.
  • Ultimately, using CRISPR does not appear to present any challenges that scientists familiar with gene editing have not already faced.

Earlier this week, reports linking the blockbuster gene-editing tool CRISPR to cancer in two studies sent investors scrambling to pull out of companies working on the technology, which is being studied for use in everything from food to medicine. The tool’s precise cut-and-paste approach to gene editing allows for a range of promising medical applications, from curing sickle cell anemia to preventing some forms of blindness.

On Monday afternoon, headlines suggested that cells edited with the tool were more likely to become cancerous. Within hours of the reports being published, shares of Editas Medicine, CRISPR Therapeutics, Intellia Therapeutics, and Sangamo Therapeutics – all of which are trying to bring CRISPR to medicine – took a significant tumble.

But scientists who study CRISPR and other methods of gene editing call the reports “overblown.” They say the link to cancer is tenuous at best and an incorrect interpretation of the results at worst.

“This is absurd,” John Doench, the associate director of the genetic perturbation platform at MIT’s Broad Institute, told Business Insider. “There was a massive overreaction here.”

Like many other researchers involved in the space, Doench read the two studies highlighted in the recent report and published in the journal Nature Medicine. Instead of concluding that the technique causes cancer, Doench read the papers and thought it highlighted facts about how cells behave in response to perceived threats. Most of these are already fairly well-known to people who study gene editing. Tweaking a cell’s DNA is a violent process; when it is done, cells respond by trying to defend or repair themselves. This is one of the biggest hurdles facing most cutting-edge gene editing approaches today. It is not unique to CRISPR.

“I’m honestly trying to figure out why this has generated such a response and I really can’t,” Doench said. “Everything I can see is just related to the stocks and finances and not in anyway related to the science.”

Cells responding normally to a perceived threat

dna cut and paste crispr

source
Samantha Lee/Business Insider

The problem comes down to the basic biology of what happens in cells that encounter DNA damage.

To make changes to DNA, CRISPR breaks key parts of the strands that make up the genetic material in a cell. This cutting and slicing ability is why it’s so powerful; previous tools for gene modification were limited by their inability to precisely target certain parts of a cell’s DNA.

When anything – be it CRISPR or a disease or anything else – slices into genetic material, the “broken” cells try to patch themselves up in a process that’s governed largely by a gene called p53.

If that fix-it gene starts to malfunction, it means cells can’t self-repair. Cancer can occur as a result.

The recent papers did not reveal that editing the DNA of a cell with CRISPR damaged its fix-it genes. Instead, the process appeared to activate them, which is exactly what scientists would expect to happen with many kinds of gene-editing.

In other words, CRISPR turned on the self-repair process, and “the cell is responding as it should,” Doench said.”That doesn’t mean p53 has been inactivated and these cells are now cancerous, it means the cell has done its job.”

A tweet that Nature sent out on Tuesday afternoon with a link to one of the papers appeared to back up this interpretation, saying, “p53 defends against CRISPR-Cas9 genome editing.”

Gaetan Burgio, a professor of genetics who studies CRISPR at the Australian National University, agreed, tweeting, “Beware exaggeration and overstated headlines. The papers say after CRISPR-Cas9 … P53 signaling is activated. They don’t say CRISPR could cause cancer.”

Laboratory cells acquire all kinds of mutations, gene-editing or not

The scientists behind the two recent papers were looking out for another potentially disturbing consequence of using CRISPR on these cells: that their fix-it genes would be shut down after applying the tool – a result that would leave them vulnerable to mutations and cancer.

But that didn’t happen either, according to the two papers. What did happen, however, is that the cells edited with CRISPR were more likely to have mutations on their fix-it genes. But that wasn’t necessarily a result of CRISPR.

In fact, cells in labs have a tendency to acquire all kinds of mutations simply as a result of being in a lab. A 2017 paper published in Nature found, for example, that human embryonic stem cell lines frequently develop mutations without any kind of gene editing being done on them. Many of those mutations also happen to be on the p53, or fix-it, gene.

The last line of one of the most recent papers sums this idea up well, concluding that scientists who are developing techniques using CRISPR should closely monitor the function of the fix-it gene on the cells that they edit using the technique.

This is also something that most biologists – especially those who work in gene editing – already know. Other techniques like zinc finger nucleases, a type of gene editing that can lead to outcomes seen as similar to CRISPR, require keeping a close eye on the fix-it gene, too. That’s a risk scientists are actively monitoring, not a unique issue presented by CRISPR.

“To anyone who would actually use gene editing, this was already baked into the cake,” Doench said.

Pin It on Pinterest